ADMA Biologics — Third Quarter 2026 Earnings Summary

ADMA Biologics reported third-quarter 2026 total revenue of $141.1 million, a 5% increase year-over-year, driven by a 31% surge in ASCENIV sales to $124.7 million. The company achieved a GAAP net income of $49.9 million and an adjusted EBITDA of $77.3 million, while expanding its gross margin to 71%. ADMA reiterated its full-year 2026 revenue guidance of at least $530 million and raised its adjusted earnings outlook, citing strong commercial momentum and constructive FDA feedback on its SG-001 development program.